ROME—Age should be no barrier to the use of novel agents for treating elderly patients with multiple myeloma, according to Michele Cavo, Associate Professor of Haematology at the University School of
Michele Cavo
ROME—Age should be no barrier to the use of novel agents for treating elderly patients with multiple myeloma, according to Michele Cavo, Associate Professor of Haematology at the University School of Medicine, Bologna, Italy, who addressed the European Expert Forum on Blood Cancer In The Elderly in Rome (19-20 March 2011). He tells eancer radio about the clinical decision-making processes needed to achieve better treatment and longer remissions among elderly patients, and explains why each patient should have therapy planned on an individual basis rather than according to chronological age.
LISTEN
[audio:https://www.audiomedica.com/podcasting/ecancer/110320MicheleCavoPODCASTmp3LoRes.mp3]